Albireo to participate at upcoming investor conferences

Boston, june 02, 2022 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare liver disease company developing novel bile acid modulators, today announced that ron cooper, president and chief executive officer will be presenting at the following investor conferences:
ALBO Ratings Summary
ALBO Quant Ranking